natgillin/translations-raw huggingface dataset:
Other medicinal products that have been reported to increase the potential toxicity of parenterally administered aminoglycosides include: - amphotericin B, cefalotin, ciclosporin, tacrolimus, polymyxins (risk of increased nephrotoxicity); - platinum compounds (risk of increased nephrotoxicity and ototoxicity); - anticholinesterases, botulinum toxin (neuromuscular effects).
- amfotericin B, cefalotin, ciklosporin, takrolimus, polimiksini (rizik od povećane nefrotoksičnosti); - spojeve koji sadržavaju platinu (rizik od povećane nefrotoksičnosti i ototoksičnosti);
BGP Products SIA Tālr: +371 676 055 80
Tālr: +371 676 055 80
Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su prikazane od težih prema blažima.
How to inhale your medicine with the Podhaler device • Only use Podhaler device contained in this pack.
Kako inhalirati Vaš lijek pomoću uređaja Podhaler
Nephrotoxicity has been reported with the use of parenteral aminoglycosides.
Nefrotoksičnost je zabilježena kod primjene parenteralnih aminoglikozida.
In a randomised, double-blind, placebo-controlled, multicentre study, TOBI Podhaler 112 mg (4 x 28 mg capsules) was administered twice daily, for three cycles of 28 days on-treatment and 28 days off-treatment (a total treatment period of 24 weeks).
Podhaler 112 mg (4 x 28 mg kapsule) primjenjivao se dvaput na dan, tijekom tri ciklusa od po 28 dana uzimanja terapije te 28 dana neuzimanja terapije (ukupno razdoblje liječenja od 24 tjedna).
• Blocked nose
• Začepljen nos
Musculoskeletal chest pain
Mišićno-koštana bol u prsnom košu
• Store the Podhaler device in its tightly closed case when not in use.
• Čuvajte uređaj Podhaler u čvrsto zatvorenom spremniku kada se ne koristi.
• Discoloration of the substance you cough up (sputum)
• Promjena boje tvari koju iskašljavate (ispljuvka)
See also “Monitoring of serum tobramycin concentrations” above.
Vidjeti također „Praćenje koncentracije tobramicina u serumu“ gore.
• Peel back the foil from the capsule card to reveal one capsule only.
• Skinite foliju s kartice s kapsulama tako da se vidi samo jedna kapsula.
The apparent terminal half-life of tobramycin in serum after inhalation of a 112 mg single dose of TOBI Podhaler was approximately 3 hours in cystic fibrosis patients and consistent with the half-life of tobramycin after inhalation of tobramycin 300 mg/5 ml nebuliser solution (TOBI).
Podhalera bio je otprilike 3 sata u bolesnika s cističnom fibrozom i u skladu s poluvijekom tobramicina nakon inhalacije tobramicin 300 mg/5 ml otopine za nebulizator (TOBI).
In clinical studies, some patients on TOBI Podhaler therapy showed an increase in aminoglycoside minimum inhibitory concentrations (MIC) for P. aeruginosa isolates tested.
Podhaler pokazali su povećanje minimalnih inhibitornih koncentracija (MIK) aminoglikozida za testirane izolate P. aeruginosa.
TOBI Podhaler 28 mg inhalation powder, hard capsules
TOBI Podhaler 28 mg prašak inhalata, tvrde kapsule
Bronchospasm can occur with inhalation of medicinal products and has been reported with TOBI Podhaler in clinical studies.
Bronhospazam koji može nastupiti nakon inhalacije lijekova zabilježen je u kliničkim ispitivanjima i uz primjenu TOBI Podhalera.
• Screw the mouthpiece on firmly until it stops.
• Čvrsto navijte nastavak za usta dok se ne zaustavi.
Replace the mouthpiece and screw it on firmly until it stops.
Vratite nastavak za usta i čvrsto ga navijte dok se ne zaustavi.
• Nosebleed
• Grlobolju
Then peel back the foil by rolling it back from the capsule card to reveal one capsule at a time, see Figures (c) and (d).
Zatim skinite foliju povlačeći je s kartice s kapsulama tako da otkrijete jednu po jednu kapsulu, vidjeti
Do not overtighten.
Pazite da ga ne navijete prečvrsto.
Based on clinical trial data the inhalation powder TOBI Podhaler was associated with a higher reported rate of cough compared with tobramycin nebuliser solution (TOBI).
Podhaler bio je povezan s većom prijavljenom stopom kašlja u usporedbi s tobramicin otopinom za nebulizator (TOBI).
Based on the interaction profile for tobramycin following intravenous and aerosolised administration, concurrent and/or sequential use of TOBI Podhaler is not recommended with other medicinal products with nephrotoxic or ototoxic potential.
Na temelju profila interakcije za tobramicin nakon intravenske primjene i aerosolom, istodobna i/ili sekvencijska primjena TOBI
56 inhalation powder, hard capsules and 1 inhaler (weekly pack) 224 (4 x 56) inhalation powder, hard capsules and 5 inhalers (monthly multipack) 448 (8 x 56) inhalation powder, hard capsules and 10 inhalers (2 x monthly multipack wrapped in foil)
56 prašak inhalata, tvrdih kapsula i 1 inhalator (tjedno pakiranje) 224 (4 x 56) prašak inhalata, tvrde kapsule i 5 inhalatora (mjesečno višestruko pakiranje)
Concomitant use of TOBI Podhaler with diuretic compounds (such as ethacrynic acid, furosemide, urea or intravenous mannitol) is not recommended.
furosemid, urea ili intravenski manitol) se ne preporučuje.
Mylan Ireland Limited Tel: +353 87 1694982
Tel: +353 87 1694982
This should be taken into account before prescribing TOBI Podhaler, considering the inhalation powder TOBI Podhaler was associated with a higher rate of cough (see above).
To se mora uzeti u obzir prije propisivanja TOBI Podhalera, budući da je prašak inhalata TOBI
Discard the empty capsule.
14. Bacite praznu kapsulu.
When the full dose (4 capsules) has been inhaled, wipe mouthpiece with a clean dry cloth.
(4 kapsule), obrišite nastavak za usta čistom, suhom krpicom.
• Set the top of the case aside.
• Odložite vrh spremnika sa strane.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING WEEKLY INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU TJEDNA UNUTARNJA KUTIJA VIŠESTRUKOG PAKIRANJA (BEZ PLAVOG OKVIRA)
BGP Products s.r.o.
BGP PRODUCTS SRL
Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first.
Unutar svakog organskog sustava nuspojave su poredane po učestalosti, od najučestalijih prema manje učestalim.
ON TOBI Podhaler OFF TOBI Podhaler
UZ TOBI Podhaler BEZ TOBI Podhalera
When to take TOBI Podhaler
Kada uzeti TOBI Podhaler
TOBI Podhaler 28 mg inhalation powder, hard capsules tobramycin
TOBI Podhaler 28 mg prašak inhalata, tvrde kapsule tobramicin
Mylan Denmark ApS Tlf: +45 28 11 69 32
Tlf: +45 28 11 69 32
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) Calcium chloride
1,2-distearoil-sn-glicero-3-fosfokolin (DSPC) kalcijev klorid sulfatna kiselina (za podešavanje pH)
• When you are ready, take your 2nd breath by repeating
• Kad ste stpremni, napravite drugi udisaj ponavljajući korak 8 i koristeći istu kapsulu.
(To be displayed only on the inner lid of the intermediate carton of multipack) Read the package leaflet before use.
(Navesti na unutrašnjosti poklopca unutarnje kutije višestrukog pakiranja) Prije uporabe pročitajte uputu o lijeku.
In the active-controlled open-label study, patients aged 20 years and older tended to discontinue more frequently with TOBI Podhaler than with the nebuliser solution; discontinuations due to adverse events accounted for about half of the discontinuations with each formulation.
Podhalerom nego otopinom za nebulizator; prekidi uzrokovani štetnim događajima odnosili su se na oko polovinu prekida kod svake formulacije.
• Only use the capsules with the inhaler provided in this pack.
• Kapsule koristite samo pomoću inhalatora priloženog u pakiranju.
Table 1 Adverse reactions Adverse reactions
Tablica 1 Nuspojave Nuspojave
Oropharnygeal pain
Orofaringealna bol
In a second open-label, multicentre study, patients received treatment with either TOBI Podhaler (112 mg) or tobramycin 300 mg/5 ml nebuliser solution (TOBI), administered twice daily for three cycles.
(112 mg) ili tobramicin 300 mg/5 ml otopinom za nebulizator (TOBI), uz primjenu dvaput na dan kroz tri ciklusa.
Clear colourless capsules containing a white to almost white powder, with “NVR AVCI” printed in blue on one part of the capsule and Novartis logo printed in blue on the other part of the capsule.
Prozirne bezbojne kapsule koje sadrže bijeli do gotovo bijeli prašak, s oznakom „NVR AVCI“
If your underlying lung disease seems worse while taking TOBI Podhaler, tell your doctor straight away.
Ako Vam se čini da se Vaša osnovna plućna bolest pogoršava dok uzimate TOBI
Mylan Healthcare Norge AS Tlf: +47 66 75 33 00
Tlf: +47 66 75 33 00
No reproduction toxicology studies have been conducted with tobramycin administered by inhalation.
Nisu provedena ispitivanja toksičnosti inhalacijskog tobramicina na reproduktivnu funkciju.
(To be displayed only on the inner lid of the outer carton of multipack) Read the package leaflet before use.
(Navesti na unutrašnjosti poklopca vanjske kutije višestrukog pakiranja) Prije uporabe pročitajte uputu o lijeku.
A numerically lower response in patients aged ≥20 years was observed: the change from baseline FEV1 observed in the patients aged ≥20 years was smaller (0.3% with TOBI Podhaler and 0.9% with TOBI nebuliser solution).
Opažen je numerički niži odgovor bolesnika u dobi ≥20 godina: promjena od početnog FEV1 opažena u bolesnika u dobi od ≥20 godina bila je manja
If you take more TOBI Podhaler than you should
Ako uzmete više TOBI
Only TOBI Podhaler capsules are to be used in the Podhaler device.
U uređaju Podhaler smiju se koristiti samo TOBI
The improvement in percent predicted FEV1 was numerically greater in the TOBI Podhaler treatment group and was statistically non-inferior to TOBI nebuliser solution.
Poboljšanje u postotku predviđenog FEV1 bilo je numerički veće u terapijskoj skupini koja je uzimala TOBI
Treatment with TOBI Podhaler for 28 days resulted in a statistically significant reduction in P. aeruginosa sputum density (-1.61 log10 CFUs), as did the nebuliser solution (-0.77 log10 CFUs).
P. aeruginosa u sputumu (-1,61 log10 CFUs), a isto je vrijedilo i za otopinu za nebulizator (-0,77 log10
After you have taken TOBI Podhaler for 28 days, you then have a 28-day break, during which you do not inhale any TOBI Podhaler.
Podhaler imat ćete stanku od 28 dana tijekom koje ne udišete
(To be displayed only on the inner lid of the outer carton of unit pack) Read the package leaflet before use.
(Navesti na unutrašnjosti poklopca vanjske kutije jediničnog pakiranja) Prije uporabe pročitajte uputu o lijeku.
There is a theoretical risk that patients being treated with TOBI Podhaler may develop P. aeruginosa isolates resistant to intravenous tobramycin over time (see section 5.1).
P. aeruginosa otporne na intravenski tobramicin (vidjeti dio 5.1).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF UNIT PACK (INCLUDING BLUE BOX)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA JEDINIČNOG PAKIRANJA (S PLAVIM OKVIROM)
How to take TOBI Podhaler
Kako uzeti TOBI Podhaler
These medicines may harm the kidneys or hearing.
Vam oštetiti bubrege ili sluh.
10 and 11.
28 dana
When patients in the placebo treatment group were switched from placebo to TOBI Podhaler at the start of the second treatment cycle, they experienced a similar improvement from baseline in percent predicted FEV1.
Podhaler na početku drugog ciklusa liječenja, doživjeli su slično poboljšanje u odnosu na početnu vrijednost u postotku predviđenog FEV1.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA VIŠESTRUKOG PAKIRANJA (S PLAVIM OKVIROM)
How to store TOBI Podhaler
Kako čuvati TOBI Podhaler
Capsule content
Podhaler kapsule.
• Place inhaler back in storage case • Twist the top of the case in a clockwise direction until it is closed tighly.
• Zavijte vrh spremnika u smjeru kazaljke na satu dok ne bude čvrsto zatvoren.
In comparison, after inhalation of a single 300 mg dose of tobramycin nebuliser solution (TOBI), sputum Cmax was 737.3 ± 1028.4 µg/g.
(TOBI), Cmax u sputumu bio je 737,3 ± 1028,4 µg/g.
Where patients are receiving several different inhaled medicinal products and chest physiotherapy, it is recommended that TOBI Podhaler is taken last.
Ako bolesnici primaju nekoliko različitih inhalacijskih lijekova i respiratornu fizioterapiju,
Storage case
Spremnik za čuvanje
Nasal congestion
Kongestija nosa
What TOBI Podhaler is used for
Za što se koristi TOBI
Place your mouth over the mouthpiece - to make a tight seal.
Postavite usne tako da njima čvrsto obujmite nastavak za usta.
Mylan Products Ltd. Tel: +44 1707 853000
Tel: +44 1707 853000
• Replace the mouthpiece and screw it on firmly until it stops.
13. • Vratite nastavak za usta i čvrsto ga navijte dok se ne zaustavi.
Hearing loss
Gubitak sluha
Each weekly carton of TOBI Podhaler contains:
Podhalera sadrži:
Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected renal dysfunction.
Podhaler propisuje bolesnicima s potvrđenom ili suspektnom bubrežnom disfunkcijom.
• Sore throat
Nadražaj grla
Wheezing
Šumovi
Mylan EPD bvba/sprl Tél/Tel: +32 2 658 61 00
Tél/Tel: +32 2 658 61 00
BGP PRODUCTS SRL Tel.: +40 372 579 000
BGP Products s.r.o. Tel: +420 222 004 400
• Stand the inhaler upright in the base of the case.
• Postavite inhalator uspravno na postolje spremnika.
BGP Products UAB Tel: +370 5 205 1288
Tel: +370 5 205 1288
PC:
CF-om.
Mylan Healthcare GmbH Tel: +49 6172 888 01
Tel: +49 6172 888 01
Mylan Medical SAS
Mylan Finland Oy
Inside your TOBI Podhaler weekly pack
Što se nalazi u tjednom pakiranju TOBI Podhalera
Dysphonia
Dispneja
Latuda lurasidone
Latuda lurasidon
Latuda has been investigated in six main studies.
Latuda je ispitan u šest glavnih ispitivanja.
The recommended starting dose is 37 mg once a day, taken with food at approximately the same time of the day.
Preporučena početna doza iznosi 37 mg jednom na dan i uzima se sa hranom u otprilike isto doba svaki dan.
Depending on the patient's response and the judgement of the treating doctor, the dose can be increased up to a maximum dose of 148 mg once a day.
Ovisno o odgovoru bolesnika i procijeni ordinirajućeg liječnika, doza se može povećati na maksimalnu dozu od 148 mg jednom na dan.
Latuda is available as tablets (18.5, 37 and 74 mg) and can only be obtained with a prescription.
Latuda je dostupan u tabletama (18,5, 37 i 74 mg) te se izdaje samo na liječnički recept.
It attaches to and affects several different receptors for neurotransmitters on the surface of nerve cells in the brain.
Vezuje se i djeluje na nekoliko različitih receptora za neurotransmitere na površini živčanih stanica u mozgu.
What is Latuda and what is it used for?
Što je Latuda i za što se koristi?
The European Commission granted a marketing authorisation valid throughout the European Union for Latuda on 21 March 2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Latuda vrijedi na prostoru Europske unije od 21. ožujka 2014.
The full EPAR and risk management plan summary for Latuda can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Latuda nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The main measure of effectiveness was the change in the patient's symptoms, measured using a standard scale for schizophrenia called ‘positive and negative syndrome scale' (PANSS).
Glavna mjera djelotvornosti bila je promjena u simptomima bolesnika što je izmjereno standardnom skalom za shizofreniju naziva „ljestvica pozitivnih i negativnih simptoma” (PANSS).
It is used to treat adults with schizophrenia, a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Koristi se za liječenje odraslih osoba koje boluju od shizofrenije, mentalne bolesti koja ima niz simptoma uključujući neorganizirano razmišljanje i govor, halucinacije (osjetila obmana (vida i sluha) kada se što pričinja), sumnje i deluzije (pogrešna vjerovanja).
What measures are being taken to ensure the safe and effective use of Latuda?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Latuda?
Other information about Latuda
Ostale informacije o lijeku Latuda
Latuda must not be used together with medicines known as ‘strong CYP3A4 inhibitors' or ‘strong CYP3A4 inducers', which may affect the levels of lurasidone in the blood.
Latuda se ne smije koristiti zajedno s lijekovima koji su poznati kao „snažni inhibitori CYP3A4” ili „snažni induktori CYP3A4”, koji mogu utjecati na razine lurasidona u krvi.
It is not intended to provide practical advice on how to use Latuda.
Svrha sažetka nije davati praktične savjete o korištenju lijeka Latuda.
What are the risks associated with Latuda?
Koji su rizici povezani s lijekom Latuda?
Since dopamine, 5-hydroxytryptamine and noradrenaline play a role in schizophrenia, by blocking their receptors lurasidone helps to normalise the activity of the brain, reducing symptoms.
Budući da dopamin, 5-hidroksitriptamin i noradrenalin igraju ulogu u shizofreniji, blokirajući njihove receptore lurasidon pomaže u normaliziranju aktivnosti mozga i ublažavanju simptoma.
Regarding safety, the side effects of Latuda were considered similar to those of other medicines of the same type, but it seemed to have fewer effects on body metabolism (such as effects on blood levels of sugar and fat, and body weight) and might have less effect on the activity of the heart than some other available treatments.
S obzirom na sigurnu primjenu, nuspojave lijeka Latuda smatrane su slične onima drugih lijekova istoga tipa, no čini se da imaju manje učinka na tjelesni metabolizam (poput djelovanja na razine šećera i masti u krvi i tjelesnu težinu), te mogu imati manje učinka na srčanu aktivnost u odnosu na neke druge dostupne terapije.
Three short-term studies compared Latuda with placebo (a dummy treatment) over six weeks in a total of 1,466 patients.
Tri kratkoročna ispitivanja usporedila su lijek Latuda sa placebom (lažnim liječenjem) u razdoblju od šest tjedana u ukupno 1.466 bolesnika.
Lurasidone acts mainly by blocking the receptors for the neurotransmitters dopamine, 5hydroxytryptamine (also called serotonin) and noradrenaline.
Lurasidon djeluje uglavnom blokirajući receptore za neurotransmitere dopamina, 5-hidroksitriptamina (naziva se također i serotonin) i noradrenalina.
This is a summary of the European public assessment report (EPAR) for Latuda.
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Latuda.
Further analyses of the results were carried out by the company, which supported the short-term benefits of treatment with Latuda.
Tvrtka je provela daljnju analizu rezultata koji podržavaju kratkoročne koristi liječenja lijekom Latuda.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Latuda's benefits are greater than its risks and recommended that it be approved for use in the EU.
Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji odlučilo je da koristi od lijeka Latuda nadmašuju s njim povezane rizike te je preporučilo njegovo odobrenje za korištenje u Europskoj uniji.
The most common side effects with Latuda (which may affect more than 1 in 10 people) are akathisia (a constant urge to move) and somnolence (sleepiness).
Najčešće nuspojave Latuda (kod više od 1 na 10 osoba) su akatizija (kontinuirana potreba za kretanjem) i somnolencija (pospanost).
One of the short-term studies was continued to 12 months (extension study) to look at the maintenance of the effect of Latuda in 292 patients, compared with quetiapine; two other studies, involving 914 patients, looked at the long-term effects of Latuda compared with another schizophrenia medicine, risperidone, or placebo, respectively.
Jedno od kratkoročnih ispitivanja produljeno je na 12 mjeseci (prošireno ispitivanje) kako bi se istražilo održavanje djelovanja lijeka Latuda u 292 bolesnika, u usporedbi s kvetiapinom; dva druga ispitivanja koja su obuhvatila 914 bolesnika istražila su dugoročna djelovanja lijeka Latuda u usporedbi s drugim lijekom za liječenje shizofrenije, risperidonom, odnosno placebom.
Why is Latuda approved?
Zašto je lijek Latuda odobren?
A risk management plan has been developed to ensure that Latuda is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Latuda.
Latuda is a medicine that contains the active substance lurasidone.
Latuda je lijek koji sadrži djelatnu tvar lurasidon.
While both shortand long-term effectiveness of Latuda have been sufficiently demonstrated, the CHMP noted that in the short-term studies its effectiveness was found to be moderate.
Iako je kratkoročno i dugoročno djelovanje lijeka Latuda dokazano u dostatnoj mjeri, CHMP je zaključio da su kratkoročna ispitivanja njegove djelotvornosti umjerena.
Lower doses should be used in patients with moderately or severely reduced kidney or liver function and in patients taking certain other medicines that may affect the levels of Latuda in the blood.
Slabije se doze trebaju koristiti u bolesnika s umjereno ili ozbiljno smanjenom funkcijom bubrega ili jetre i u bolesnika koji uzimaju određene druge lijekove koji mogu utjecati na koncentracije Latuda u krvi.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Latuda, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku, za lijek Latuda uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju primjenjivati.
Latuda was not shown to be as effective as risperidone in the second study, although the available data supported a long-term benefit.
U drugom ispitivanju nije dokazano da je Latuda podjednako djelotvoran kao risperidon, iako dostupni podaci govore u prilog dugoročnim koristima.
The active substance in Latuda, lurasidone, is an antipsychotic medicine.
Djelatna tvar lijeka Latuda, lurasidon, je antipsihotik.
What benefits of Latuda have been shown in studies?
Koje su koristi lijeka Latuda dokazane u ispitivanjima?
The last study showed that 30% of patients treated with Latuda relapsed within one year, compared with 41% of patients treated with placebo.
Posljednje je ispitivanje dokazalo da je 30% bolesnika liječenih lijekom Latuda imalo relaps unutar jedne godine, u usporedbi sa 41% bolesnika liječenih placebom.
In the extension study, 21% of patients treated with Latuda had a relapse within one year, compared with 27% of patients treated with quetiapine, showing that Latuda was at least as effective as quetiapine.
U proširenom ispitivanju, 21% bolesnika liječeno lijekom Latuda imalo je relaps u roku od godine dana, u usporedbi s 27% bolesnika liječenih kvetiapinom, čime se dokazuje da je lijek Latuda barem u jednakoj mjeri učinkovit kao kvetiapin.
In these long-term studies, the effectiveness of Latuda was measured by the percentage of patients who relapsed and had symptoms of schizophrenia coming back during treatment.
U ovim dugoročnim ispitivanjima, djelotvornost lijeka Latuda izmjerena je postotkom bolesnika u relapsu te onima kojima su se simptomi shizofrenije vraćali tijekom liječenja.
For more information about treatment with Latuda, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Latuda pročitajte u uputama o lijeku (također dio EPAR-a) odnosno obratite se svom liječniku ili ljekarniku.
For practical information about using Latuda, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju lijeka Latuda pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
How is Latuda used?
Kako se Latuda koristi?
How does Latuda work?
Kako djeluje Latuda?